Accession | ARO:3007040 |
Definition | A combination therapy for multidrug resistant pathogens consisting of two cephalosporin antibiotics (cefotaxime and ceftiofur) with two beta-lactamase inhibitors (tazobactam and clavulanate) encapsulated in a nanoparticle. They were shown to have efficient antimicrobial activity against multidrug resistant extended-spectrum beta-lactamase producing Enterobacteriaceae. |
Drug Class | cephalosporin |
Classification | 10 ontology terms | Show + process or component of antibiotic biology or chemistry + resistance-modifying agents + inhibitor of antibiotic resistance mechanism + antibiotic molecule + beta-lactam antibiotic + beta-lactamase inhibitor + serine beta-lactamase inhibitor + cephem + cephalosporin [Drug Class] + beta-lactam derived beta-lactamase inhibitor |
Parent Term(s) | 5 ontology terms | Show + antibiotic mixture + has_part clavulanic acid [Adjuvant] + has_part tazobactam [Adjuvant] + has_part ceftiofur [Antibiotic] + has_part cefotaxime [Antibiotic] |
Publications | Fan P, et al. 2022. Int J Biol Macromol 195:506-514 A novel combination therapy for multidrug resistant pathogens using chitosan nanoparticles loaded with β-lactam antibiotics and β-lactamase inhibitors. (PMID 34920071) |